Sofia Waissbluth1. 1. Department of Otolaryngology, Pontificia Universidad Católica de Chile, Santiago, Chile. sofia.waissbluth@mail.mcgill.ca.
Abstract
BACKGROUND: Cisplatin (CDDP) chemotherapy can cause serious side effects including irreversible and progressive hearing loss. Studies have aimed to assess potential protective strategies; however, systemic treatments have presented variable results, and potential interactions with CDDP have limited clinical trials. METHODS: A review of the literature was performed in order to evaluate clinical trials that have studied a transtympanic approach as an otoprotectant strategy. RESULTS: Six clinical trials were included. While a transtympanic approach can limit side effects and avoid interactions with CDDP, recurrent issues have been expressed including which otoprotectant to test, time delays between CDDP treatment and transtympanic injections, side effects such as pain and dizziness, concentrations, and number of injections. Clinical trials have used sodium thiosulfate, N-acetylcysteine and dexamethasone. CONCLUSIONS: While a transtympanic approach seems like an attractive strategy, further research is needed to clarify which is the optimal otoprotectant, its dosage, and the number of injections.
BACKGROUND:Cisplatin (CDDP) chemotherapy can cause serious side effects including irreversible and progressive hearing loss. Studies have aimed to assess potential protective strategies; however, systemic treatments have presented variable results, and potential interactions with CDDP have limited clinical trials. METHODS: A review of the literature was performed in order to evaluate clinical trials that have studied a transtympanic approach as an otoprotectant strategy. RESULTS: Six clinical trials were included. While a transtympanic approach can limit side effects and avoid interactions with CDDP, recurrent issues have been expressed including which otoprotectant to test, time delays between CDDP treatment and transtympanic injections, side effects such as pain and dizziness, concentrations, and number of injections. Clinical trials have used sodium thiosulfate, N-acetylcysteine and dexamethasone. CONCLUSIONS: While a transtympanic approach seems like an attractive strategy, further research is needed to clarify which is the optimal otoprotectant, its dosage, and the number of injections.
Authors: Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Marilyn F Dille; Dawn Konrad-Martin; Frederick Gallun; Wendy J Helt; Jane S Gordon; Kelly M Reavis; Gene W Bratt; Stephen A Fausti Journal: J Am Acad Audiol Date: 2010-06 Impact factor: 1.664
Authors: Kristin R Knight; Lu Chen; David Freyer; Richard Aplenc; Mary Bancroft; Bonnie Bliss; Ha Dang; Biljana Gillmeister; Eleanor Hendershot; Dale F Kraemer; Lanie Lindenfeld; Jane Meza; Edward A Neuwelt; Brad H Pollock; Lillian Sung Journal: J Clin Oncol Date: 2016-12-12 Impact factor: 44.544
Authors: Silvia Murillo-Cuesta; Adelaida M Celaya; Blanca Cervantes; Jose M Bermúdez-Muñoz; Lourdes Rodríguez-de la Rosa; Julio Contreras; Isabel Sánchez-Pérez; Isabel Varela-Nieto Journal: Clin Transl Med Date: 2021-04
Authors: Lauren K Dillard; Lucero Lopez-Perez; Ricardo X Martinez; Amanda M Fullerton; Shelly Chadha; Catherine M McMahon Journal: Cancer Epidemiol Date: 2022-06-17 Impact factor: 2.890